Appili Therapeutics Advances with FDA Approvals and Funding
Company Announcements

Appili Therapeutics Advances with FDA Approvals and Funding

Appili Therapeutics Inc Class A (TSE:APLI) has released an update.

Appili Therapeutics Inc. has reported a milestone achievement with the FDA approval and subsequent commercial launch of LIKMEZ™, a metronidazole oral suspension for treating anaerobic bacterial infections. The company has also secured significant funding from the U.S. Air Force Academy to advance its biodefense vaccine candidate, ATI-1701, towards an IND submission. Additionally, Appili is progressing with its antiparasitic product, ATI-1801, which is in advanced clinical development and may qualify for a priority review voucher.

For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAppili Shareholders Approve Acquisition by Aditxt
TheFlyAditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801
TipRanks Canadian Auto-Generated NewsdeskAppili Therapeutics’ FDA Alignment and Aditxt Acquisition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App